1. Home
  2. PLUT vs IRD Comparison

PLUT vs IRD Comparison

Compare PLUT & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLUT
  • IRD
  • Stock Information
  • Founded
  • PLUT 2018
  • IRD 2018
  • Country
  • PLUT Hong Kong
  • IRD United States
  • Employees
  • PLUT N/A
  • IRD N/A
  • Industry
  • PLUT
  • IRD
  • Sector
  • PLUT
  • IRD
  • Exchange
  • PLUT NYSE
  • IRD NYSE
  • Market Cap
  • PLUT 35.6M
  • IRD 38.8M
  • IPO Year
  • PLUT 2025
  • IRD N/A
  • Fundamental
  • Price
  • PLUT $2.37
  • IRD $0.95
  • Analyst Decision
  • PLUT
  • IRD Strong Buy
  • Analyst Count
  • PLUT 0
  • IRD 2
  • Target Price
  • PLUT N/A
  • IRD $7.00
  • AVG Volume (30 Days)
  • PLUT 39.5K
  • IRD 184.2K
  • Earning Date
  • PLUT 01-01-0001
  • IRD 05-15-2025
  • Dividend Yield
  • PLUT N/A
  • IRD N/A
  • EPS Growth
  • PLUT N/A
  • IRD N/A
  • EPS
  • PLUT N/A
  • IRD N/A
  • Revenue
  • PLUT $1,435,597.00
  • IRD $10,992,000.00
  • Revenue This Year
  • PLUT N/A
  • IRD $22.00
  • Revenue Next Year
  • PLUT N/A
  • IRD $100.89
  • P/E Ratio
  • PLUT N/A
  • IRD N/A
  • Revenue Growth
  • PLUT 1.42
  • IRD N/A
  • 52 Week Low
  • PLUT $2.10
  • IRD $0.65
  • 52 Week High
  • PLUT $4.22
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • PLUT N/A
  • IRD N/A
  • Support Level
  • PLUT N/A
  • IRD N/A
  • Resistance Level
  • PLUT N/A
  • IRD N/A
  • Average True Range (ATR)
  • PLUT 0.00
  • IRD 0.00
  • MACD
  • PLUT 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • PLUT 0.00
  • IRD 0.00

About PLUT PLUTUS FINANCIAL GROUP LIMITED

Plutus Financial Group Ltd provides financial services. It mainly offers (i) securities dealings and brokerage services (ii) margin financing services and (iii) underwriting and placing services.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: